Qvex Adverse Reactions

Quetiapine has been associated with a low incidence of extrapyramidal symptoms but tardive dyskinesia may occur after long-term treatment.
Rises in prolactin concentrations may be less than with chlorpromazine.
The most frequent adverse effects with Quetiapine are somnolence and dizziness. Mild asthenia, anxiety, fever, rhinitis, peripheral edema, constipation, dyspepsia, dry mouth and raised liver enzyme values are also relatively common. Orthostatic hypotension associated with dizziness, tachycardia, and syncope has been reported, particularly during initial dose-titration. Prolongation of QT interval is rarely significant with Quetiapine. Hyperglycaemia and exacerbation of pre-existing diabetes have been reported rarely. Clinical monitoring for hyperglycaemia has been recommended, especially in patients with, or at risk of developing, diabetes. Weight gain, particularly during early treatment, has also been noted. Neuroleptic malignant syndrome is rare with Quetiapine. Leucopenia, neutropenia and eosinophilia have also been reported. Other adverse effects have included rises in plasma-triglyceride and cholesterol concentrations, and reduced plasma-thyroid hormone concentrations. There have been rare reports of seizures, hypersensitivity reactions including angioedema, and priapism.
Breast feeding: Mother receiving Quetiapine 200 mg daily by mouth has been reported to excretion of the drug through breast milk, the patients receiving Quetiapine should not breast feed.
Dementia: In the treatment of behavioural problems in elderly patients with dementia showed an increased risk of mortality with certain drugs of this class, including Quetiapine; most of the deaths appeared due to cardiovascular events or infection.
Effects on the blood: There have been reports of leucopenia, neutropenia and pancytopenia associated with Quetiapine therapy; when the drug was stopped. Thrombotic thrombocytopenic purpura has also been reported in a patient who received Quetiapine.
Effects on body-weight: The increased risk of weight gain with some atypical antipsychotics.
Effects on carbohydrate metabolism: The increased risk of glucose intolerance and diabetes mellitus with some atypical antipsychotics, including Quetiapine has been reported.
Effects on lipid metabolism: The increased risk of hyperlipidaemia with some atypical antipsychotics is reported.
Effects on the pancreas: Severe haemorrhagic pancreatitis and necrotising pancreatitis may occur.
Effects on the respiratory system: Hyperventilation and respiratory alkalosis have been reported with Quetiapine use. Acute respiratory failure may develop in patients with a history of chronic obstructive pulmonary disease with even a single 50-mg dose of Quetiapine.
Quetiapine has been associated with mania. In old man with schizophrenia developed manic symptoms after starting treatment with Quetiapine; the symptoms resolved when Quetiapine was withdrawn.